相关实验视频

Updated: Jan 16, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

为未来的PSMA抑制剂铺平道路:对结构修饰的比较临床前评估的见解

Katarína Hajduová¹, Kateřina Dvořáková Bendová¹, Miloš Petřík^1,2,3

¹Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Hnevotinska 1333/5, Olomouc, 77900, Czech Republic.

EJNMMI radiopharmacy and chemistry

|September 26, 2025

概括

三种新的前列腺特异性膜抗原 (PSMA) 抑制剂被评估为前列腺癌成像. P19在诊断成像和潜在的治疗应用方面显示出最有前途的特征.

科学领域:

放射化学和核医学放射化学和核医学
药用化学医学化学
在瘤学瘤学.

背景情况:

前列腺特异性膜抗原 (PSMA) 是前列腺癌诊断和治疗的关键目标.
新的PSMA抑制剂 (P15,P16,P19) 是通过对PSMA-617的结构修改而开发的.
修改包括逆合成策略和二基链接剂.

研究的目的:

在临床前评估新型PSMA抑制剂 (P15,P16,P19).
评估结构修改对物理化学性质,体外行为和体外药理动学的影响.
为了研究用-68 (68Ga) 进行放射性标记.

主要方法:

合成和放射标记P15,P16和P19与68Ga.
在人体血中评估放射化学纯度和稳定性.
分割系数和血蛋白结合的测量.
使用LNCaP细胞进行体外细胞吸收研究.
在瘤携带小鼠的体内PET/CT成像和生物分布研究.

主要成果:

所有化合物的高放射性化学纯度 (>98%) 和稳定性都得到了实现.
化合物表现出水友特性,与不同程度的血蛋白结合.
在体外观察到类似的细胞吸收和内部化.
所有的抑制剂都在体内表现出瘤向能力.
在稳定性,结合性和瘤吸收方面,P19显示出最有利的形状.

结论:

链接器中的立体化学修改显著影响了抑制器的行为.
P19是前列腺癌进一步研究的一个有前途的候选人.
双基可能是一个有利的链接器构建块.
在前列腺癌中具有诊断成像 (68Ga) 和治疗应用 (例如,卢-177,177Lu) 的潜力.

关键词:

在PSMA上,PSMA可以在PSMA上进行交易.在临床前使用的PET/CT.前列腺癌是什么意思前列腺癌是什么意思放射性药物放射性药物放射性药物热门节目热门节目热门节目

更多相关视频

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Published on: January 26, 2024

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

相关概念视频

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...